We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer
News

Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer

Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer
News

Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ganymed Pharmaceuticals AG has announced that the first patients are being enrolled and are starting treatment in a Phase I/II OVAR clinical trial to assess the safety, tolerability, and efficacy of IMAB027 as single agent for the treatment of advanced ovarian cancer.

IMAB027 is a highly specific monoclonal antibody targeting the tight junction protein Claudin-6 (CLDN6). The trial is being conducted in Germany, Belgium, Russia, and Ukraine.

“IMAB027 is the second antibody from Ganymed to enter clinical development that is based on our Ideal Monoclonal Antibody platform,” said Dr. Özlem Türeci, Chief Executive Officer and Chief Medical Officer of Ganymed.

Dr. Türeci continued, “Women with recurrent ovarian cancer have few therapeutic options. We believe that the unmatched cancer-cell selectivity of IMAB027 holds great promises of improving treatment options for these patients.”

Advertisement